Activist investor William Ackman on Monday said there will be no "crown jewel" asset sales at Valeant Pharmaceuticals International Inc. (VRX), but that the company would consider the sale on non core assets.

Mr. Ackman, who holds a board seat at the drug company, also told CNBC in an interview that Valeant's board "absolutely" would take up the issue of potential roll backs to some of the company's drug prices. The Valeant board, he said, would take up the issue "promptly."

The Pershing Square Holdings Ltd. chief executive also said that a renaming of the company is a possibility.

CNBC website: www.cnbc.com

Write to nymonitoring@dowjones.com

 

(END) Dow Jones Newswires

May 02, 2016 13:19 ET (17:19 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Pershing Square (EU:PSH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Pershing Square 차트를 더 보려면 여기를 클릭.
Pershing Square (EU:PSH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Pershing Square 차트를 더 보려면 여기를 클릭.